Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 13/20 | 0.41 |
| ▸ | CES1 | P23141 | 10/20 | 0.41 |
| ▸ | CES2 | O00748 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28092074 | 0.74 | EPHX1 (0.49) | EPHX1FAAHCES1CES2MEN1 | |
| SCHEMBL19949895 | 0.70 | EPHX1 (0.47) | EPHX1FAAHCES1CES2MEN1 | |
| SCHEMBL7541904 | 0.69 | EPHX1 (0.80) | EPHX1FAAHCES1CES2MEN1 | |
| SCHEMBL7535349 | 0.69 | EPHX1 (0.80) | EPHX1FAAHCES1CES2MEN1 | |
| SCHEMBL7545639 | 0.69 | EPHX1 (0.80) | EPHX1FAAHCES1CES2MEN1 | |
| SCHEMBL7542772 | 0.69 | EPHX1 (0.80) | EPHX1FAAHCES1CES2MEN1 | |
| SCHEMBL7539813 | 0.68 | EPHX1 (0.77) | EPHX1FAAHCES1CES2MEN1 | |
| SCHEMBL7536039 | 0.68 | EPHX1 (0.77) | EPHX1FAAHCES1CES2MEN1 | |
| SCHEMBL7539126 | 0.67 | EPHX1 (0.75) | EPHX1MEN1KMT2A | |
| SCHEMBL7539129 | 0.67 | EPHX1 (0.65) | EPHX1FAAHCES1CES2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0777498-B1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | DCLRE1B, RNASE1, DCLRE1A | EPHX1 3665/4885FAAH 4856/4885CES1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.